Department of Health & Human Services

Adverse Event Expedited Report - Multiple Agents v4.0

Public Health Service National Institutes of Health National Cancer Institute Bethesda, Maryland 20892

INSTRUCTIONS: Use this form to submit an Expedited Report for an Adverse Event (AE) or Death Unrelated to an Adverse Event for NCI clinical trials using one investigational agent sponsored under an NCI IND. Refer to the protocol to determine if NCI IND agents are utilized on the study and how to submit the Expedited Report. <u>Use this form only when it is impossible to access the Adverse Event Expedited Reporting System (AdEERS) Web application</u>. The AdEERS Web application can be accessed at https://webapps.ctep.nci.nih.gov/openapps/plsql/gadeers main\$.startup.

This form must be completed using the <u>AdEERS Template Instructions</u> available from the NCI CTEP Help Desk by phone at (301) 840-8202 or by fax at (301) 948-2242. Information components followed by "1," "LOV," "LOV,FT," or "CTC" must be entered using the special instructions below. Please see the <u>AdEERS Template Instructions</u> for a complete description of all components and instructions developed for this template.

- Date information must be entered in MM/DD/YYYY format except where "MM/YYYY Only" (month and year only) instruction is given.
- LOV Information must be entered using standardized values from the AdEERS List of Values (LOV) document available from the AdEERS Web site.
- LOV/FT Information must be entered using the AdEERS LOV or, if an appropriate value cannot be found, using Free Text (values other than those listed in the LOV).
- Adverse Events are to be reported using the terminology and criteria of the NCI Common Toxicity Criteria (CTC), Version 2.0 (publish date April 30, 1999).

COMPLETING THE REPORT:

- 1. Complete all MANDATORY COMPONENTS in MANDATORY SECTIONS. Complete all Requisite Components in MANDATORY SECTIONS if relevant to the patient.
- 2. Determine which Requisite Sections apply to the patient and complete the MANDATORY COMPONENTS (if any) and Requisite Components if relevant to the patient.
- 3. If additional space is required to complete a report section, copy the page where the section appears, complete your entries, and attach to the final report.
- 4. Complete the form using black or blue ink and send to the Investigational Drug Branch (IDB), P.O. Box 30012, Bethesda, MD 20824 or fax to 301-230-0159.

1. PROTOCOL INFORMATION - THIS SECTION IS MANDATORY FOR ALL EXPEDITED REPORTS

	IS THIS AN AMENDMENT TO A PREVIOUSLY	IF YES, CHECK AMENDM								
NCI PROTOCOL NUMBER	SUBMITTED REPORT? □YES □NO	NUMBER: □1 □2 □3	INITIAL EXPE	INITIAL EXPEDITED REPORT TICKET NUMBER (AMENDMENTS ONLY)						
PROTOCOL TITLE (Continue below)										
2. REPORTER INFORMAT	TION – THIS SECTION IS MANDAT	ORY FOR ALL EXPED	ITED REPORTS							
REPORT DATE ¹	LAST NAME	FIRST NAME	PHONE	FAX	E-MAIL					
REPORTER										
HYSICIAN INFORMATION (Physician o be consulted for questions)				-						
		· · · · · · · · · · · · · · · · · · ·		Fax is a requisite component for PHYSICIAN INFORMATION	t					
	N – THIS SECTION IS MANDATOR lication code associated with each patient ent		D REPORTS							
PATIENT ID		JTION NAME, CITY, AND STA ed, see http://ctep.cancer.gov	•	ODE – Institution where patient	is registered on the protocol or					
BIRTH DATE (MM/YYYYOnly) RACE LO	GENDER LOV	HEIGHT (cm)	WEIGHT (kg)	Baseline Performa Protocol – ECOG/	nce Status at Initiation of Zubrod Scale ^{LOV}					
100										
DISEASE NAME ^{Lov}			e Not Listed (Enter a s _i entered in the DISEASE N	pecific disease name when "Soli IAME component)	d Tumor NOS" or "Hematolog					
PRIMARY SITE OF DISEASE LOV		Other Primar	y Site of Disease (Ent	er only when an appropriate pri	mary site is not found in the LC					

February 12, 2002 Page 1 of 4

4. COURSE INFORMA	ATION – THIS SECTION IS MAN					
			4C) is a unique ident over X hr D1-3 / eve		associated with each ar	m or dose level of the protocol
Treatment Assignment Code		""""""""""""""""""""""""""""""""""""""	0,61,7,111, 11, 13, 6,4,	ciy 5 weeks		
If the appropriate TAC is un	available from the LOV or is unknown,	items A through D	(below) are mandate	ory for the tre	atment arm or dose leve	l.
A. Agent Nam	B. $B.$	Dose	C. Administration R	oute ^{LOV}	D. Duration	and Schedule LOV
	-					
START DATE OF FIRST COURSE	E 1 START DATE OF	COURSE ASSOCIATE	ED WITH EXPEDITED RE	PORT 1 ST	ART DATE OF PRIMARY AE	1
End Date of AE 1	COURSE NUMB	ER ON WHICH AE OC	CURRED	TO:	TAL NUMBER OF COURSES	S TO DATE
	EVENT - THIS SECTION IS MAN	DATORY FOR A	LL EXPEDITED RI	EPORTS		
DECOME HOW AND INCAMEN	o. Ermiloj (condide pelon)					
	ecord Fatal/Death or Recovered/Resolved w then Date of Recovery or Death [see right]		e of Recovery or Dea	ith ^I	HAS PATIENT BEEN R	ETREATED (TO DATE)? LIYES LING
	M PROTOCOL TREATMENT (TO DATE)? UYE. oved from Protocol Treatment (see right)		e Removed from Prot	tocol Treatme	nt ^I	
6. DEATH UNRELATE	D TO ADVERSE EVENT – MANI	DATORY ONLY I	F DEATH IS UNRI	ELATED TO	AN AE	
Sections 1, 2, 3, 4, 5, 6, 7	and 10 are mandatory when reporting a d	eath caused by suici	ide, accident, progress	sive disease, et	c.	
CAUSE OF DEATH LOV (If you rec SYSTEM FAILURE CAUSING DEATH	ord Progressive Disease as the CAUSE OF DEATH	, then PRIMARY ORGAN	PRIMARY ORGAN SY	/STEM FAILURI	E CAUSING DEATH LOV	
	- THIS SECTION IS MANDATORY FO	OR ALL EXPEDI	TED REPORTS			
THERAPY LOV (Fo (If you record any of the following as 1 column 6] is mandatory: bone marro	OR THE PRIMARY DISEASE) IHERAPY, then PRIOR THERAPY AGENT NAME(S) [In ow transplant, chemotherapy [NOS], chemotherapy mic], hormonal therapy, or immunotherapy)	THERAPY START DATE (If known) (MM/YYYY only)	Therapy End Date	Enter additiona for diseases oth	Comments I therapies, prior therapy er than primary disease, cluded in LOV, if needed)	PRIOR THERAPY AGENT NAME(S) ^{LOV} (See note in THERAPY column)
	dition(s) — This section is requiredition(s) the patient experienced prior t			xisting Co	nditions	
CONDITION A LOV	CONDITION B LOV	Pre-Existing (Condition Not Listed	(Enter only whe	n an appropriate condition	is not found in the LOV)
9. Site(s) of Metastat	tic Disease – This section is r	equired if the	patient has Site	es of Metas	static Disease	
SITE A LOV	SITE B LOV	Sites of Metas	tatic Disease Not Lis	ted (Enter only	when an appropriate site is	not found in the LOV)

February 12, 2002 Page 2 of 4

PROTOCOL AGENT(S) – THIS SECTION IS MANDATORY FOR ALL EXPEDITED REPORTS AGENT NAME(S) LOV AGENT NAME D LOV AGENT NAME A LOV AGENT NAME B LOV AGENT NAME C LOV DATE LAST ADMINISTERED 1 (This is mandatory for crossover studies if an investigational agent was administered at any time, see Section 4) TOTAL DOSE ADMINISTERED THIS COURSE UNIT OF MEASURE LOV UNIT OF MEASURE LOV UNIT OF MEASURE LOV LINIT OF MEASURE LOV (Amount of agent given for current dose or cycle, this is not total dose given to date) Comments Agent Adjustment LOV □Yes □No □Yes □No □Yes □No $\square Yes \square No$ Was administration delayed? If yes, complete Duration Delay below If yes, complete Duration Delay below If yes, complete Duration Delay below If ves, complete Duration Delay below $\square sec \square min$ $\square sec \square min$ $\square sec \square min$ $\square sec \square min$ □hrs □days □hrs □days □hrs □days □hrs □days Duration Delay (Enter duration length and check Unit of Measure) CROSSOVER STUDIES - Instruction is provided in Section 4 regarding required information for reports associated with Crossover Studies. 11. Concomitant Medication(s) – This section is required if any non-protocol medication may have contributed to the event(s) CONCOMITANT MEDICATION A CONCOMITANT MEDICATION B CONCOMITANT MEDICATION C CONCOMITANT MEDICATION D 12. Other Contributing Cause(s) – This section is required if Other Causes may have contributed to the Adverse Event OTHER CONTRIBUTING CAUSE A OTHER CONTRIBUTING CAUSE B OTHER CONTRIBUTING CAUSE C OTHER CONTRIBUTING CAUSE D 13. ADVERSE EVENTS (CTC) – THIS SECTION IS MANDATORY FOR ALL EXPEDITED REPORTS EXCEPT DEATH UNRELATED TO AE ADVERSE EVENT CTC GRADE CTC Hospitalization or *If AE is other, Specify:* Comments CATEGORY CTC Prolongation of (If an appropriate AE term cannot (Enter other relevant (If you record a GRADE 3 or higher, Hospitalization be identified in the CTC, identify information in this column) Hospitalization or Prolongation the CTC CATEGORY and provide AE (See note in of Hospitalization information in this column) **GRADE** column) (in column 5) is mandatory) AE A: $\square Yes \square No$ AE B: $\square Yes \square No$ AE C: $\square Yes \square No$ 14. ATTRIBUTION FOR ADVERSE EVENT – THIS SECTION IS MANDATORY FOR ALL EXPEDITED REPORTS EXCEPT DEATH UNRELATED TO AE Attribution is the determination whether an AE is related to a medical treatment or procedure. Evaluate each AE the patient experiences to determine what might have caused the event or what interventions or conditions the event might have been attributed to.

IMPORTANT: Every AdEERS report that includes Adverse Events must include for each Adverse Event at least one attribution of Possible, Probable, or Definite to either the Agent, the Disease, Other Causes, or Concomitant Medications. NCI will not accept reports without at least one attribution of Possible, Probable, or Definite to either the Agent, the Disease, Other Causes, or Concomitant Medications for each Adverse Event.

Write the AE term(s) you used in Section 13 in the heading area of columns 2, 3, and 4 (found on page 4). Complete the AGENT NAME, DISEASE, Concomitant Medication and/or Other Contributing Causes Information in column 1 using the same information you provided in Sections 10, 3, 11, and 12. Circle the ATTRIBUTION CODE in each column for each AE based on its relationship to the AGENT NAME, DISEASE, Concomitant Medication and/or Other Contributing Causes information provided in column 1. An example is provided below.

Example	Anorexia					i	Bilirubii	า		Pain-Other						
	ADVER	ADVERSE EVENT CTC (AE A from Section 13)					ADVERSE EVENT CTC (AE B from Section 13)					ADVERSE EVENT CTC (AE C from Section 13)				
Drug 1 AGENT NAME LOV (from Section 10)	_ 1	2	3	4	5	1	2	3	4	5	1	2	3	4	5	

ATTRIBUTION CODES are defined as:

- Unrelated The Adverse Event is clearly NOT related to the investigational agent, disease, concomitant medication, or other contributing cause.
- The Adverse Event is doubtfully related to the investigational agent, disease, concomitant medication, or other contributing cause.
- 3 The Adverse Event may be related to the investigational agent, disease, concomitant medication, or other contributing cause.
- Probable The Adverse Event is likely related to the investigational agent, disease, concomitant medication, or other contributing cause.

The Adverse Event is clearly related to the investigational agent, disease, concomitant medication, or other contributing cause.

This section continues on page 4.

14. ATTRIBUTION FOR ADVERSE EVENT (Continued)

	ADVER	SE EVEN	IT CTC (AE A	A from S	ection 13)	ADVERS	E EVENT	CTC (AE I	B from Se	ection 13)	ADVER	ADVERSE EVENT CTC (AE C from Section 13)						
	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5			
AGENT NAME LOV (AGENT NAME A from Section																		
AGENT NAME LOV (AGENT NAME B from Section	1 10)	2	3	4	5	1	2	3	4	5	1	2	3	4	5			
	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5			
AGENT NAME LOV (AGENT NAME C from Section	10)																	
AGENT NAME LOV (AGENT NAME D from Section	10)	2	3	4	5	1	2	3	4	5	1	2	3	4	5			
,	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5			
DISEASE NAME ^{LOV} (from Section 3)																		
Concomitant Medication (A from Section 11)	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5			
conconnant incaccion (11 from section 11)	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5			
Concomitant Medication (B from Section 11)		_	•	·		·	_		•	•	•	_		•				
Concomitant Medication (C from Section 11)	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5			
Concomium Medication (C. from section 11)	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5			
Concomitant Medication (D from Section 11)	_ '		3	7	3	•	_	3	•	J	•	_	3	7	3			
	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5			
Other Contributing Causes (A from Section 12)	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5			
Other Contributing Causes (B from Section 12)	'	2	3	4	5	ı	2	3	4	3	ı	2	3	4	5			
	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5			
Other Contributing Causes (C from Section 12)					_				_	_			_		_			
Other Contributing Causes (D from Section 12)	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5			
15. Abnormal and Relevant Nor This section is not required if Microbiol						ion is red	quired	d if La	borat	ory Resul	lts are r	elevan	t to th	e repo	ort			
This section is not required if the rootor	ogy myorman	sii is pro	Baselin		10.			Λ	ladir/W	orst			Recover	y/Lates	t			
Lab ^{LOV/FT}	Date 1		Value	l	Unit of Me	easure ^{LOV}	1	Date ¹		Value		Date	1]	Value			
Lab A:																		
Lab B:																		
Lab C:																		
16. Lab: Microbiology — This se Do not complete Section 15 if Microbiol					ng infec	ctions												
Infection Type: Bacterial Fungal	Viral																	
injection Type. Diacterial DI ungui D	rirai	Site					Date ¹					Infection	ous Age	nt				
17. Additional Information Attac Check those you have attached for subm				requir	ed if rel	levant to	the re	eport										
□ Autopsy Report □ Consults		-		$\exists Flow$	Sheets/CR	Fs □Labo	oratory	Reports	$\Box \alpha$	ther informat	tion specif	iv·						
□ Pathology Report □ Progress Note					ral Letters				nt to IRB		, specij	· ·						
18. Submitter Signature – This s				-				_			ion 21							
10. Suominer Signature – This s			U					-	·			a farth	o cara c	of thic n	ation			
Loortify that this Evandited Danet	nas uttii le	vieweu	anu app	noved	uy a pilyS	ociali Uf lil	e mea	ically C	-iuneu	ucsignee f	SPUNSIO	e iur til	c care (n uns β	auen			
I certify that this Expedited Report				T NAMF DI										E-MAIL				
	FIRST NAME				PHO	NE			Fax			E-MAIL						

February 12, 2002 Page 4 of 4